AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Nuo Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026
- Market cap
- $60.99M
- P/E (TTM)
- –
- Dividend yield
- –
Nuo Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $1.69M | $1.22M | $1.02M | $957.10K | $625.20K | $484.38K | $394.87K | $370.95K | $364.77K | $234.58K | $197.02K | $232.24K | 95.6% | +170.5% |
| Aurix and Private Label Kits [Member] | $1.62M | – | – | – | – | – | – | – | – | – | – | – | 91.5% | – |
| License [Member] | $77.94K | $77.94K | $75.00K | $75.00K | $75.00K | $0 | $0 | $0 | $0 | – | – | – | 4.4% | +3.9% |
| Aurix and Private Label Centrifuge Devices [Member] | $72.00K | – | – | – | – | – | – | – | – | – | – | – | 4.1% | – |
By region
From the segment and revenue-disaggregation notes of Nuo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.